Skip to main content

Table 2 Availability of outcome data for included trials

From: Delays in reporting and publishing trial results during pandemics: cross sectional analysis of 2009 H1N1, 2014 Ebola, and 2016 Zika clinical trials

Outcome; n (%) unless noted Total
(n = 333)
H1N1
(n = 261; 78%)
Ebola
(n = 60; 18%)
Zika
(n = 12; 4%)
Registry Outcomes
  Results available in registry within 12 months of primary completion date 15 (5%) 11 (4%) 4 (7%) 0 (0%)
  Results available in registry at any time 158 (47%) 144 (55%) 13 (22%) 1 (8%)
  No results in registry 175 (53%) 117 (45%) 47 (78%) 11 (92%)
  Time from completion to results in registry among trials with registry results, months; median (IQR) 41.5 (16–76) 34 (16–76) 29 (14–43) n/a
Publication Outcomes
  Published within 24 month of primary completion date 129 (39%) 94 (36%) 29 (48%) 6 (50%)
  Published at any time 228 (69%) 181 (69%) 41 (68%) 6 (50%)
  Not published 105 (32%) 80 (31%) 19 (32%) 6 (50%)
  Time from completion to publication among published trials, months; median (IQR) 21 (9–34) 23 (13–34) 16 (0–34) n/a
Combined Registry and Publication Outcomes
  Registry has results within 12 months of completion or published within 24 months 139 (42%) 100 (38%) 33 (55%) 6 (50%)
  Registry has results within 12 months of completion and published within 24 months 5 (2%) 5 (2%) 0 (0%) 0 (0%)
  Published and results in registry 112 (34%) 100 (38%) 11 (18%) 1 (8%)
  Published but no results in registry 116 (35%) 81 (31%) 30 (50%) 5 (42%)
  Not published but results are in registry 46 (14%) 44 (17%) 2 (3%) 0 (0%)
  Not published and no results in registry 59 (18%) 36 (14%) 17 (28%) 6 (50%)